BRIEF-Kashiv Biosciences submits Biologics License Application to the U.S. FDA and receives European Medicines Agency acceptance for ADL-018

Reuters

Oct 06

Oct 6 (Reuters) - Alvotech SA ALVO.O:

KASHIV BIOSCIENCES ANNOUNCES SUBMISSION OF BIOLOGICS LICENSE APPLICATION TO U.S. FDA AND ACCEPTANCE OF MARKET AUTHORIZATION APPLICATION BY EUROPEAN MEDICINES AGENCY FOR ADL-018, A PROPOSED BIOSIMILAR TO XOLAIR® (OMALIZUMAB)

Source text: ID:nBwblfJYra

Further company coverage: ALVO.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2573674016"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2573674016\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2573674016?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-06 20:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2573674016","market":"nz","top_or_hot":-1,"title":"BRIEF-Kashiv Biosciences submits Biologics License Application to the U.S. FDA and receives European Medicines Agency acceptance for ADL-018","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Kashiv Biosciences submits Biologics License Application to the U.S. FDA and receives European Medicines Agency acceptance for ADL-018</title></head><body><p><span>Oct 6 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/ALVO\">Alvotech</a> SA <span>ALVO.O</span>:</p><ul><li><p>KASHIV BIOSCIENCES ANNOUNCES SUBMISSION OF BIOLOGICS LICENSE APPLICATION TO U.S. FDA AND ACCEPTANCE OF MARKET AUTHORIZATION APPLICATION BY EUROPEAN MEDICINES AGENCY FOR ADL-018, A PROPOSED BIOSIMILAR TO XOLAIR® (OMALIZUMAB)</p></li></ul><p>Source text: <span>ID:nBwblfJYra</span></p><p>Further company coverage: <span>ALVO.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Kashiv Biosciences submits Biologics License Application to the U.S. FDA and receives European Medicines Agency acceptance for ADL-018</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Kashiv Biosciences submits Biologics License Application to the U.S. FDA and receives European Medicines Agency acceptance for ADL-018\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-06 20:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Kashiv Biosciences submits Biologics License Application to the U.S. FDA and receives European Medicines Agency acceptance for ADL-018</title></head><body><p><span>Oct 6 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/ALVO\">Alvotech</a> SA <span>ALVO.O</span>:</p><ul><li><p>KASHIV BIOSCIENCES ANNOUNCES SUBMISSION OF BIOLOGICS LICENSE APPLICATION TO U.S. FDA AND ACCEPTANCE OF MARKET AUTHORIZATION APPLICATION BY EUROPEAN MEDICINES AGENCY FOR ADL-018, A PROPOSED BIOSIMILAR TO XOLAIR® (OMALIZUMAB)</p></li></ul><p>Source text: <span>ID:nBwblfJYra</span></p><p>Further company coverage: <span>ALVO.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nTUA22TF0N:1","article_id":"2573674016","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2573674016","pubTimestamp":1759752573,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Kashiv Biosciences submits Biologics License Application to the U.S. FDA and receives European Medicines Agency acceptance for ADL-018Oct 6 (Reuters) - Alvotech SA ALVO.O:KASHIV BIOSCIENCES ANNO","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4007":"制药","AMRX":"Amneal Pharmaceuticals, Inc.","ALVO":"Alvotech"},"translate_title":"简介-Kashiv Biosciences向美国FDA提交生物制品许可申请，并获得欧洲药品管理局对ADL-018的受理","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALVO":0.9,"AMRX":0.9},"content_text":"BRIEF-Kashiv Biosciences submits Biologics License Application to the U.S. FDA and receives European Medicines Agency acceptance for ADL-018Oct 6 (Reuters) - Alvotech SA ALVO.O:KASHIV BIOSCIENCES ANNOUNCES SUBMISSION OF BIOLOGICS LICENSE APPLICATION TO U.S. FDA AND ACCEPTANCE OF MARKET AUTHORIZATION APPLICATION BY EUROPEAN MEDICINES AGENCY FOR ADL-018, A PROPOSED BIOSIMILAR TO XOLAIR® (OMALIZUMAB)Source text: ID:nBwblfJYraFurther company coverage: ALVO.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}